Christlieb A R, Krolewski A S, Warram J H
Joslin Diabetes Center, Boston, Massachusetts 02215.
Am J Cardiol. 1987 Dec 14;60(17):61I-65I. doi: 10.1016/0002-9149(87)90462-0.
Diabetic nephropathy is manifested by albuminuria, hypertension and progressive loss of renal function. Only one-third of patients with insulin-dependent diabetes mellitus of juvenile onset develop nephropathy and the risk of nephropathy does not increase with increasing duration of diabetes. Hypertension occurs almost exclusively in patients with nephropathy. Therefore, there is a subset of patients at risk for both nephropathy and hypertension. It is important to identify the patients destined to develop nephropathy, to define the pathophysiology responsible for the nephropathy in this subset of patients and to develop programs to interrupt the pathophysiology early in its course and hopefully prevent the progression to end-stage renal failure. Potential markers to identify patients who will develop nephropathy include a family history of hypertension, increased glomerular filtration rate and renal mass and presence of significant microalbuminuria. Studies are needed to evaluate various classes of drugs for their efficacy in altering the pathophysiologic hemodynamic changes leading to nephropathy.
糖尿病肾病表现为蛋白尿、高血压和肾功能进行性丧失。青少年起病的胰岛素依赖型糖尿病患者中只有三分之一会发生肾病,且肾病风险不会随糖尿病病程延长而增加。高血压几乎仅发生于肾病患者。因此,有一部分患者同时面临肾病和高血压风险。识别注定会发生肾病的患者、明确该类患者肾病的病理生理学机制以及制定在病程早期阻断病理生理学过程并有望预防进展至终末期肾衰竭的方案非常重要。用于识别将发生肾病患者的潜在标志物包括高血压家族史、肾小球滤过率增加、肾体积增大以及显著微量白蛋白尿的存在。需要开展研究来评估各类药物在改变导致肾病的病理生理血流动力学变化方面的疗效。